This inventor holds 1 USPTO granted patent. Top assignees: Memorial Sloan Kettering Cancer Center, Stevens Institute of Technology, University of Illinois. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:



Years Active: 2023
Title: Lucia Wang and Research on Antiestrogen Compounds.
Introduction
Lucia Wang is an inventor associated with Jersey City, New Jersey. Her patent work includes research into antiestrogen compounds designed to target estrogen receptor alpha (ERα), a receptor relevant to breast cancer.
Latest Patents
Wang is associated with 1 patent, titled “Antiestrogen Compounds.” The patent describes a genus of proteolysis-targeting chimera (PROTAC)-type compounds that can act as selective estrogen receptor degraders (SERDs) and estrogen receptor antagonists. These compounds are designed to bind ERα and recruit cellular components that degrade or antagonize the receptor in breast cancer cells.
The described compounds exhibit antiproliferative effects and may have potential for treating breast cancer, either alone or in combination with other therapies. The patent presents this approach as a way to combine an ERα-targeting ligand with a recognition motif, or degron, to direct the receptor for degradation.
Career Highlights
The information provided associates Wang with the University of Illinois and Memorial Sloan Kettering Cancer Center. These affiliations connect her work to academic and cancer research settings.
Collaborations
Wang’s listed coworkers include Abhishek Sharma and Shengjia Lin. Their names are associated with the research context provided for her patent work.
Conclusion
Lucia Wang’s patent focuses on PROTAC-type antiestrogen compounds that target ERα, an approach with potential relevance to breast cancer treatment.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile